Key facts
- This page summarizes Rahul Singhvi's Form 4 filing for Kairos Pharma, LTD. (KAPA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Nov 2025, 17:26.
Rahul Singhvi - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)
- Reporting relationship
- Director
- Issuer ticker
- KAPA
- Reported as of
- 08 Oct 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Nov 2025, 17:26:43 UTC
- Prior SEC filing
- 12 Jun 2025
- Next SEC filing
- 18 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rahul Singhvi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rahul Singhvi filed Form 4 for Kairos Pharma, LTD. (KAPA) on 26 Nov 2025.
Change
- Previous filing in this sequence was filed on 12 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001322731
Primary reporting owner
Singhvi Rahul
- Relationship
- Director
- Address
- C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES
- Signature
- /s/ Rahul Singhvi
- Signature date
- 26 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KAPA
transaction
COMMON STOCK
Award
- Transaction value
- $0
- Shares
- +19,084
- Change %
- +63%
- Price
- $0.000000
- Shares after
- 49,204
- Date
- 08 Oct 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
Footnote F2
Consists of 49,204 RSUs which remain subject to vesting.